A Study of LY2584702 in Participants With Advanced Cancer

Phase 1 Terminated 34 enrolled Eli Lilly and Company

SequentialOpen-labelTreatment

Summary

The main purpose of this trial is to determine a recommended Phase 2 dose of LY2584702 that may be safely administered to participants with advanced/metastatic cancer.

Timeline

Start: 2008-11
Primary completion: 2011-04
Completion: 2011-04

Outcome

Outcome not reported

Stopped: “The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.”

Publications

Tolcher A, Goldman J, Patnaik A, Papadopoulos KP, Westwood P, Kelly CS, Bumgardner W, Sams L, Geeganage S, Wang T, Capen AR, Huang J, Joseph S, Miller J, Benhadji KA, Brail LH, Rosen LS. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur J Cancer. 2014 Mar;50(5):867-75. doi: 10.1016/j.ejca.2013.11.039. Epub 2014 Jan 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2584702	Small molecule	25 mg	Oral
Subject	LY2584702	Small molecule	50 mg	Oral
Subject	LY2584702	Small molecule	75 mg	Oral
Subject	LY2584702	Small molecule	100 mg	Oral
Subject	LY2584702	Small molecule	200 mg	Oral
Subject	LY2584702	Small molecule	300 mg	Oral